Reports to Medarex. During the Term, Celldex shall keep Medarex informed of its development and commercialization activities subject to this Agreement with respect to Royalty-Bearing Products, including the filing of an IND or the initiation of a clinical trial, and on January 31 of each year shall provide Medarex with a reasonably detailed written summary of such events and activities in the preceding year.
Appears in 4 contracts
Samples: Assignment and License Agreement (Celldex Therapeutics Inc), Assignment and License Agreement (Celldex Therapeutics Inc), Assignment and License Agreement (Celldex Therapeutics Inc)
